ANTAGONATE
Clinical safety rating
cautionComprehensive clinical and safety monograph for ANTAGONATE (ANTAGONATE).
Comprehensive clinical and safety monograph for ANTAGONATE (ANTAGONATE).
FDA-approved for the treatment of major depressive disorder (MDD) as an adjunctive therapyOff-label use for treatment-resistant depression (TRD)Off-label use for neurodegenerative disorders such as Alzheimer's disease
Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.
| Metabolism | Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes. Minor contributions from CYP2D6 and CYP1A2. |
| Excretion | Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other |
| Half-life | Terminal: 12 hours (range 10-14) in adults; allows twice-daily dosing |
| Protein binding | 92% bound primarily to albumin |
| Volume of Distribution | 0.4 L/kg, indicating distribution primarily in extracellular fluid |
| Bioavailability | Oral: 85% with high first-pass effect; IM: 100% |
| Onset of Action | IV: 1 minute; oral: 30 minutes (on empty stomach) |
| Duration of Action | IV: 2-4 hours; oral: 6-8 hours at steady state |
| Molecular Weight | 470.6 |
3 mg subcutaneously once daily, with dose adjustment based on drug levels.
| Dosage form | TABLET |
| Renal impairment | No adjustment for GFR > 30 mL/min; reduce dose by 50% for GFR 15-30 mL/min; avoid for GFR < 15 mL/min. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | Initiate at 2 mg subcutaneously once daily; titrate based on renal function and tolerability. |
| 1st trimester | Insufficient human data; animal studies show no teratogenic effects, but caution advised. Use only if potential benefit outweighs risk. |
| 2nd trimester | Limited human data; no known fetal harm, but monitor for effects on fetal growth and amniotic fluid volume. Use if clearly needed. |
| 3rd trimester | Risk of neonatal adaptation syndrome if used near term; avoid in third trimester unless essential. |
Clinical note
Comprehensive clinical and safety monograph for ANTAGONATE (ANTAGONATE).
| Placental transfer | Crosses placenta; fetal serum levels approximately 10-20% of maternal levels. |
| Breastfeeding | Excreted in breast milk in low amounts; unlikely to cause adverse effects in term infants. Consider risks and benefits, especially in preterm or ill infants. |
| Lactation Rating | L2 (Limited data - probably compatible) |
| Teratogenic Risk | ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Use effective contraception during treatment. |
| Fetal Monitoring | Pregnancy testing prior to initiation and monthly during therapy. Ultrasound monitoring for fetal growth, amniotic fluid volume, and renal development if pregnancy occurs. Monitor maternal renal function and blood pressure closely. |
| Fertility Effects | Antagonate may impair female fertility based on animal studies showing ovarian dysfunction and reduced implantation. Reversible upon discontinuation. Male fertility effects include reduced spermatogenesis and sperm motility. Advise patients of potential impact on fertility. |
■ FDA Black Box Warning
WARNING: Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication.
| Serious Effects |
Known hypersensitivity to drug or excipientsSignificant hepatic impairment (Child-Pugh Class B or C)Use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)Current or recent (within 2 weeks) use of MAO inhibitors
| Precautions | Increased risk of suicidal ideation and behavior in children, adolescents, and young adults, May impair cognitive and motor function; caution when driving or operating machinery, Contraindicated in patients with known hypersensitivity to the drug or its components, Use with caution in patients with hepatic impairment, due to reduced drug clearance, May cause QT prolongation; avoid use in patients with congenital long QT syndrome or concurrent use of QT-prolonging drugs |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase ANTAGONATE levels and risk of toxicity. Limit alcohol intake to prevent excessive hypotension or sedation. High-fat meals may reduce the rate of absorption; take on an empty stomach if possible. No other significant food interactions known. |
| Clinical Pearls | ANTAGONATE is a high-affinity, slowly dissociating beta-blocker. Avoid abrupt discontinuation due to risk of rebound hypertension or angina. Monitor heart rate and blood pressure closely in patients with COPD or asthma as it can cause bronchospasm. Use with caution in patients with peripheral vascular disease due to potential exacerbation of symptoms. Dose adjustment required in hepatic impairment but not renal. May mask tachycardia of hypoglycemia in diabetic patients. |
| Patient Advice | Take exactly as prescribed, at the same time each day. · Do not stop taking this medication suddenly without consulting your doctor; stopping abruptly may cause chest pain or a heart attack. · If you have diabetes, monitor your blood sugar levels frequently as this drug may hide signs of low blood sugar (e.g., fast heartbeat). · Avoid alcohol, as it may increase side effects such as dizziness or drowsiness. · Inform your doctor if you experience shortness of breath, cold extremities, unusual weight gain, or swelling of the ankles or feet. · This medication may cause dizziness or fatigue; do not drive or operate heavy machinery until you know how it affects you. |
Loading safety data…